arctigenin has been researched along with Lung Adenocarcinoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| An, H; Chen, Y; Guo, S; Shi, S; Wang, X; Zhan, Y; Zhang, H | 1 |
| Inafuku, M; Iwasaki, H; Oku, H; Susanti, S; Taira, N | 1 |
2 other study(ies) available for arctigenin and Lung Adenocarcinoma
| Article | Year |
|---|---|
Arctigenin, a novel TMEM16A inhibitor for lung adenocarcinoma therapy.
Topics: Adenocarcinoma of Lung; Animals; Anoctamin-1; Antineoplastic Agents; Cell Line; Furans; Humans; Lignans; Lung Neoplasms; MAP Kinase Signaling System; Mice, Inbred BALB C | 2020 |
Mechanism of arctigenin-mediated specific cytotoxicity against human lung adenocarcinoma cell lines.
Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents, Phytogenic; Apoptosis; Arctium; Cell Cycle Proteins; Cell Line; Cyclin E; Cyclin-Dependent Kinase 2; Cyclins; Down-Regulation; Furans; Glutathione; Humans; Lignans; Lung Neoplasms; Nuclear Proteins; Oncogene Proteins; Phytotherapy; Plant Extracts; Proto-Oncogene Proteins c-akt; Signal Transduction | 2013 |